184 related articles for article (PubMed ID: 37903899)
21. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ; Kutlu Y; Mutlu E; Aykan MB; Korkmaz M; Yalçın S; Şakalar T; Celayir ÖM; Kayıkçıoğlu E; Aslan F; Hafızoğlu E; Altıntaş YE; Keskinkılıç M; Chalabiyev E; Çelebi A; Dursun B; Kapar C; Özen M; Acar Ö; Dülgar Ö; Kut E; Biter S; Kus F; Almuradova E; Erdoğan AP; Saray S; Güven DC; Şimşek ET; Üskent N; Kemal Y; Çakar B; Açıkgöz Ö; Kılıçkap S; Aksoy S
Int J Clin Oncol; 2024 Mar; 29(3):258-265. PubMed ID: 38310597
[TBL] [Abstract][Full Text] [Related]
22. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
[TBL] [Abstract][Full Text] [Related]
23. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Pizzuti L; Giordano A; Michelotti A; Mazzotta M; Natoli C; Gamucci T; De Angelis C; Landucci E; Diodati L; Iezzi L; Mentuccia L; Fabbri A; Barba M; Sanguineti G; Marchetti P; Tomao S; Mariani L; Paris I; Lorusso V; Vallarelli S; Cassano A; Aroldi F; Orlandi A; Moscetti L; Sergi D; Sarobba MG; Tonini G; Santini D; Sini V; Veltri E; Vaccaro A; Ferrari L; De Tursi M; Tinari N; Grassadonia A; Greco F; Botticelli A; La Verde N; Zamagni C; Rubino D; Cortesi E; Magri V; Pomati G; Scagnoli S; Capomolla E; Kayal R; Scinto AF; Corsi D; Cazzaniga M; Laudadio L; Forciniti S; Mancini M; Carbognin L; Seminara P; Barni S; Samaritani R; Roselli M; Portarena I; Russo A; Ficorella C; Cannita K; Carpano S; Pistelli M; Berardi R; De Maria R; Sperduti I; Ciliberto G; Vici P
J Cell Physiol; 2019 Jun; 234(6):7708-7717. PubMed ID: 30536609
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib combined with endocrine therapy in heavily pretreated HR
Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
[TBL] [Abstract][Full Text] [Related]
25. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Finn RS; Boer K; Bondarenko I; Patel R; Pinter T; Schmidt M; Shparyk YV; Thummala A; Voitko N; Bananis E; McRoy L; Wilner K; Huang X; Kim S; Slamon DJ; Ettl J
Breast Cancer Res Treat; 2020 Sep; 183(2):419-428. PubMed ID: 32683565
[TBL] [Abstract][Full Text] [Related]
26. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
27. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
Rugo HS; Liu X; Li B; McRoy L; Chen C; Layman RM; Brufsky A
Int J Cancer; 2024 Feb; 154(4):701-711. PubMed ID: 37831416
[TBL] [Abstract][Full Text] [Related]
28. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
29. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.
Mycock K; Zhan L; Hart K; Taylor-Stokes G; Milligan G; Atkinson C; Mitra D
Future Oncol; 2022 Jan; 18(3):349-362. PubMed ID: 34842454
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of palbociclib-based therapy in women with HR+/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study.
Shangguan CF; Jiang M; Yang C; Lou GY; Li YT; Qu Q
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(19):6138-6148. PubMed ID: 34661274
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Rugo HS; Finn RS; Diéras V; Ettl J; Lipatov O; Joy AA; Harbeck N; Castrellon A; Iyer S; Lu DR; Mori A; Gauthier ER; Bartlett CH; Gelmon KA; Slamon DJ
Breast Cancer Res Treat; 2019 Apr; 174(3):719-729. PubMed ID: 30632023
[TBL] [Abstract][Full Text] [Related]
32. Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data.
Masuda N; Kosaka N; Iwata H; Toi M
Int J Clin Oncol; 2021 Dec; 26(12):2179-2193. PubMed ID: 34698970
[TBL] [Abstract][Full Text] [Related]
33. Real-world study of palbociclib combined with endocrine therapy for patients with metastatic breast cancer: A comparison of subsequent treatment patterns and HER2 expression analysis.
Liang X; Zhang L; Gui X; Di L; Li H; Song G
Cancer; 2024 Apr; 130(S8):1476-1487. PubMed ID: 38198366
[TBL] [Abstract][Full Text] [Related]
34. Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study.
Shen L; Zhou J; Chen Y; Ding J; Wei H; Liu J; Xia W; Xie B; Xie X; Li X; Dai Y; Zhang G; Qiu X; Li C; Sun S; Chen W; Gong D; Li H; Huang J; Jiang X; Ni C
Cancer Med; 2022 Nov; 11(22):4157-4168. PubMed ID: 35470572
[TBL] [Abstract][Full Text] [Related]
35. Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Karuturi MS; Cappelleri JC; Blum JL; Patel K; Telivala B; McCune S; Cuevas JD; Lakhanpal S; Montelongo MZ; Wang Y; Tripathy D; Rocque GB
J Geriatr Oncol; 2024 Jan; 15(1):101670. PubMed ID: 38061288
[TBL] [Abstract][Full Text] [Related]
36. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Lynce F; Blackburn MJ; Zhuo R; Gallagher C; Hahn OM; Abu-Khalaf M; Mohebtash M; Wu T; Pohlmann PR; Dilawari A; Tiwari SR; Chitalia A; Warren R; Tan M; Shajahan-Haq AN; Isaacs C
Cancer; 2021 Oct; 127(19):3622-3630. PubMed ID: 34157782
[TBL] [Abstract][Full Text] [Related]
37. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
Sun J; Zhong X; Ma J; Sun W; Han HS; Soliman HH; Loftus LS; Costa RLB; Armaghani AJ; Soyano-Muller AE; Czerniecki BJ; Lee MC; Kiluk JV; Khakpour N; Hoover SJ; Laronga C; Khong HT
Cancer Med; 2021 Nov; 10(21):7665-7672. PubMed ID: 34590788
[TBL] [Abstract][Full Text] [Related]
38. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Ettl J; Im SA; Ro J; Masuda N; Colleoni M; Schnell P; Bananis E; Lu DR; Cristofanilli M; Rugo HS; Finn RS
Breast Cancer Res; 2020 Mar; 22(1):27. PubMed ID: 32164785
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal A; Matthews CM; Levine EG; Salerno KE; Zhang F; Takabe K; Early AP; Edge SB; O'Connor T; Khoury T; Young JS; Opyrchal M
Clin Breast Cancer; 2018 Dec; 18(6):e1401-e1405. PubMed ID: 29778787
[TBL] [Abstract][Full Text] [Related]
40. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
